1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in Type 2 diabetes. N Engl J Med. 2015;373:2117-28. doi:10.1056/NEJMoa1504720.
2. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377:644-57. doi:10.1056/NEJMoa1611925.
3. Wiviott SD, Raz I, Bonaca MP. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380:347-57. doi:10.1056/NEJMoa1812389.
4. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90-100. doi:10.1177/1479164114559852.
5. Hayashi M, Shimizu W, Albert CM. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015;116:1887-1906. doi:10.1161/CIRCRESAHA.116.304521.
6. Verschure DO, van Eck-Smit BL, Somsen GA, Knol RJ, Verberne HJ. Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation. Neth Heart J. 2016;24:701-8. doi:10.1007/s12471-016-0902-y.
7. Kubota Y, Yamamoto T, Tara S, Tokita Y, Yodogawa K, Iwasaki Y, et al. Effect of Empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: rationale. Diabetes Ther. 2018;9:2107-16. doi:10.1007/s13300-018-0480-7.
8. O’Gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-e425. doi:10.1161/CIR.0b013e3182742cf6.
9. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:2354-94. doi:10.1161/CIR.0000000000000133.
10. Barthel P, Schneider R, Bauer A, Ulm K, Schmitt C, Schömig A, et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation. 2003;108:1221-6. doi:10.1161/01.CIR.0000088783.34082.89.
11. Abe A, Kobayashi K, Yuzawa H, Sato H, Fukunaga S, Fujino T, et al. Comparison of late potentials for 24 hours between Brugada syndrome and arrhythmogenic right ventricular cardiomyopathy using a novel signal-averaging system based on Holter ECG. Circ Arrhythm Electrophysiol. 2012;5:789-95. doi:10.1161/CIRCEP.111.969865.
12. Yoshioka K, Amino M, Zareba W, Shima M, Matsuzaki A, Fujii T, et al. Identification of high-risk Brugada syndrome patients by combined analysis of late potential and T-wave amplitude variability on ambulatory electrocardiograms. Circ J. 2013;77:610-8. doi:10.1253/circj.cj-12-0932.
13. Hashimoto K, Kasamaki Y, Soma M, Takase B. Diurnal variation of frequency domain T-wave alternans on 24-hour ambulatory electrocardiogram in subjects without heart disease: Significant effect of autonomic nervous activity of the heart. Ann Noninvasive Electrocardiol. 2019;24:e12620. doi:10.1111/anec.12620.
14. Ulgen MS, Akdemir O, Toprak N. The effects of trimetazidine on heart rate variability and signal-averaged electrocardiography in early period of acute myocardial infarction. Int J Cardiol. 2001;77:255-62. doi:10.1016/s0167-5273(00)00441-1.
15. Lampert R, Ickovics JR, Viscoli CJ, Horwitz RI, Lee FA. Effects of propranolol on recovery of heart rate variability following acute myocardial infarction and relation to outcome in the beta-blocker Heart Attack Trial. Am J Cardiol. 2003;91:137-42. doi:10.1016/s0002-9149(02)03098-9.
16. Matthews VB, Elliot RH, Rudnicka C, Hricova J, Herat L, Schlaich MP. Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2. J Hypertens. 2017;35:2059-68. doi:10.1097/HJH.0000000000001434.
17. Kiuchi S, Hisatake S, Kabuki T, Fujii T, Oka T, Dobashi S, et al. Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report. Drug Discov Ther. 2018;12:51-4. doi:10.5582/ddt.2017.01069.
18. Schwartz PJ. The autonomic nervous system and sudden death. Eur Heart J. 1998;19:F72-F80. doi:10.1053/euhj.1998.1292.
19. Yamagata K, Horie M, Aiba T, Ogawa S, Aizawa Y, Ohe T, et al. Genotype-phenotype correlation of SCN5A mutation for clinical and electrocardiographic characteristics of probands with Brugada Syndrome: A Japanese multicenter registry. Circulation. 2017;135:2255-70. doi:10.1161/CIRCULATIONAHA.117.027983.
20. Shimizu W, Makimoto H, Yamagata K, Kamakura T, Wada M, Miyamoto K, et al. Association of genetic and clinical aspects of congenital long QT syndrome with life-threatening arrhythmias in Japanese patients. JAMA Cardiol. 2019;4:246-54. doi:10.1001/jamacardio.2018.4925.
21. Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, et al. AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation. 2004;109:990-6. doi:10.1161/01.CIR.0000117090.01718.2A.
22. Bigger JT, Jr., Fleiss JL, Steinman RC, Rolnitzky LM, Kleiger RE, Rottman JN. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation. 1992;85:164-71. doi:10.1161/01.cir.85.1.164.
23. Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death. Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation. 1992;85 :I77-91.
24. Schmidt G, Malik M, Barthel P, Schneider R, Ulm K, Rolnitzky L, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet. 1999;353:1390-6. doi:10.1016/S0140-6736(98)08428-1.
25. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333-9. doi:10.1007/s00125-016-3956-x.
26. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, et al. How does Empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018;41:356-63. doi:10.2337/dc17-1096.
27. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180-93. doi:10.1111/dom.12572.
28. Sano M. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity. J Cardiol. 2018;71:471-6. doi:10.1016/j.jjcc.2017.12.004.
30. Kario K, Okada K, Kato M, Nishizawa M, Yoshida T, Asano T, et al. 24-hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2018;139:2089-97. doi:10.1161/CIRCULATIONAHA.118.037076. [Epub ahead of print]
31. Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with Type 2 diabetes. Diabetes. 2016;65:1190-5. doi:10.2337/db15-1356.
32. Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A ‘Thrifty Substrate’ hypothesis. Diabetes Care. 2016;39:1108-14. doi:10.2337/dc16-0330.
33. Arima Y, Izumiya Y, Ishida T, Takashio S, Ishii M, Sueta D, et al. Myocardial ischemia suppresses ketone body utilization. J Am Coll Cardio. 2019;73:246-7. doi:10.1016/j.jacc.2018.10.040.
34. Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M, et al. Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats. J Pharmacol Exp Ther. 2019;368:524-34. doi:10.1124/jpet.118.253666.
35. van der Meer P, Lipsic E. Erythropoietin: repair of the failing heart. J Am Coll Cardiol. 2006;48:185-6. doi:10.1016/j.jacc.2006.04.007.
36. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844-7. doi:10.14740/jocmr2760w.
37. Packer M, Anker SD, Butler J, Filippatos G, Zannad F. Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action. JAMA Cardiol. 2017;2:1025-9. doi:10.1001/jamacardio.2017.2275.
38. Cao WH, Morrison SF. Disinhibition of rostral raphe pallidus neurons increases cardiac sympathetic nerve activity and heart rate. Brain Res. 2003;980:1-10. doi:10.1016/s0006-8993(03)02981-0.
39. Chiba Y, Yamada T, Tsukita S, Takahashi K, Munakata Y, Shirai Y, et al. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, acutely reduces energy expenditure in BAT via neural signals in mice. PLOS ONE. 2016;11:e0150756. doi:10.1371/journal.pone.0150756.
40. Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 2017;8:1077. doi:10.3389/fphys.2017.01077.
41. Matsutani D, Sakamoto M, Iuchi H, Minato S, Suzuki H, Kayama Y, et al. Glycemic variability in continuous glucose monitoring is inversely associated with baroreflex sensitivity in type 2 diabetes: a preliminary report. Cardiovasc Diabetol 2018;17:36. doi: 10.1186/s12933-018-0683-2.
42. Williams SM, Eleftheriadou A, Alam U, Cuthbertson DJ, Wilding JPH. Cardiac autonomic neuropathy in obesity, metabolic syndrome and prediabetes: A narrative review. Diabetes Ther 2019;10:1995-2021. doi: 10.1007/s13300-019-00693-0.
43. Tran HV, Gore JM, Darling CE, Ash AS, Kiefe CI, Goldberg RJ. Hyperglycemia and risk of ventricular tachycardia among patients hospitalized with acute myocardial infarction. Cardiovasc Diabetol 2018;17:136. doi: 10.1186/s12933-018-0779-8.
44. Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Bollow A, et al. Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias. Cardiovasc Diabetol 2018;17:125. doi: 10.1186/s12933-018-0768-y.
45. van Bommel EJM, Smits MM, Ruiter D, Muskiet MHA, Kramer MHH, Nieuwdorp M, et al. Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes. J Hypertens 2020. Online ahead of print.
46. Zhang N, Feng B, Ma X, Sun K, Xu G, Zhou Y. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction. Cardiovasc Diabetol 2019;18:107. doi: 10.1186/s12933-019-0914-1.
47. Durak A, Olgar Y, Degirmenci S, Akkus E, Tuncay E, Turan B. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol 2018;17:144. doi: 10.1186/s12933-018-0790-0.
48. Beitelshees AL, Leslie BR, Taylor SI. Sodium-glucose cotransporter 2 inhibitors: A case study in translational research. Diabetes 2019;68:1109-20. doi: 10.2337/dbi18-0006.
49. Coleman RL, Gray AM, Broedl Md UC, Fitchett D, George JT, Woerle HJ, et al. Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels? Diabetes Obes Metab 2020;22:1151-6.
50. Handelsman Y. Rationale for the early use of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Adv Ther 2019;36:2567-86. doi: 10.1007/s12325-019-01054-w.